/AVXL

AVXL Stock - Anavex Life Sciences Corp.

Q: What is the analyst price target for AVXL?

Analyst price target information is not currently available for AVXL.

Q: What is AVXL's market cap?

Market capitalization information is not currently available for AVXL.

Healthcare|Biotechnology|NASDAQ

$4.64+8.16%

+$0.35 (+8.16%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+137.1%upside

Target: $11.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AVXL

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.17

52W High$13.99

52W Low$2.86

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	$-52,877,000	$-55,756,000	$-50,986,000	$-41,921,000
Net Income	N/A	$-43,002,000	$-47,505,000	$-47,978,000	$-37,909,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.54	$-0.52	$-0.60	$-0.62	$-0.54

Company Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Visit Website

Earnings History & Surprises

AVXL

Beat Rate

67%

Last 18 quarters

Avg Surprise

+7.0%

EPS vs Estimate

Beats / Misses

12/5

1 met exactly

Latest EPS

$-0.11

Q4 2025

EPS Surprise History

Q1 24

+26.7%

$-0.11vs$-0.15

Q2 24

0.0%

$-0.13vs$-0.13

Q3 24

+6.7%

$-0.14vs$-0.15

Q4 24

+17.6%

$-0.14vs$-0.17

Q1 25

+17.6%

$-0.14vs$-0.17

Q2 25

+18.8%

$-0.13vs$-0.16

Q3 25

-23.1%

$-0.16vs$-0.13

Q4 25

+15.4%

$-0.11vs$-0.13

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Feb 11, 2026	$-0.10	—	—	—
Q4 2025	Nov 25, 2025	$-0.13	$-0.11	+15.4%	✓ BEAT
Q3 2025	Aug 12, 2025	$-0.13	$-0.16	-23.1%	✗ MISS
Q2 2025	May 13, 2025	$-0.16	$-0.13	+18.8%	✓ BEAT
Q1 2025	Feb 12, 2025	$-0.17	$-0.14	+17.6%	✓ BEAT
Q4 2024	Dec 23, 2024	$-0.17	$-0.14	+17.6%	✓ BEAT
Q3 2024	Aug 6, 2024	$-0.15	$-0.14	+6.7%	✓ BEAT
Q2 2024	May 9, 2024	$-0.13	$-0.13	0.0%	= MET
Q1 2024	Feb 7, 2024	$-0.15	$-0.11	+26.7%	✓ BEAT
Q4 2023	Nov 27, 2023	$-0.16	$-0.12	+25.0%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.17	$-0.14	+17.6%	✓ BEAT
Q2 2023	May 9, 2023	$-0.18	$-0.17	+5.6%	✓ BEAT
Q1 2023	Feb 7, 2023	$-0.20	$-0.17	+15.0%	✓ BEAT
Q4 2022	Nov 28, 2022	$-0.16	$-0.18	-12.5%	✗ MISS
Q3 2022	Aug 9, 2022	$-0.15	$-0.16	-6.7%	✗ MISS
Q2 2022	May 10, 2022	$-0.16	$-0.14	+12.5%	✓ BEAT
Q1 2022	Feb 9, 2022	$-0.16	$-0.14	+12.5%	✓ BEAT
Q4 2021	Nov 24, 2021	$-0.13	$-0.15	-15.4%	✗ MISS
Q3 2021	Aug 12, 2021	$-0.13	$-0.14	-7.7%	✗ MISS

Frequently Asked Questions about AVXL

What is AVXL's current stock price?

Anavex Life Sciences Corp. (AVXL) is currently trading at $4.64 per share. The stock has moved +8.16% today.

What is the analyst price target for AVXL?

The average analyst price target for AVXL is $11.00, based on 1 analyst.

What sector is Anavex Life Sciences Corp. in?

Anavex Life Sciences Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is AVXL's market cap?

Anavex Life Sciences Corp. has a market capitalization of $0.41 billion, making it a small-cap company.

Does AVXL pay dividends?

No, Anavex Life Sciences Corp. does not currently pay a dividend to shareholders.